<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Pharmacological therapy for Type 2 (non-insulin-dependent) <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> aims at controlling <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> to delay or prevent complications associated with the disease </plain></SENT>
<SENT sid="1" pm="."><plain>Most patients with Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> present with both stimulated insulin deficiency and <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>In general, the former can manifest as postprandial <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> and the latter as fasting <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e>, though a definitive association has not been established </plain></SENT>
<SENT sid="3" pm="."><plain>Emerging data show a high failure rate of long-term monotherapy and establishes the significance of mealtime glycaemia and the role of postprandial <z:chebi fb="105" ids="17234">glucose</z:chebi> excursions in the development and progression of vascular complications </plain></SENT>
<SENT sid="4" pm="."><plain>To overcome such failures of monotherapy and to address the different underlying defects of the pathology of Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, a combined therapy of oral <z:chebi fb="0" ids="35526">antidiabetic</z:chebi> agents with complementary modes of action should be considered </plain></SENT>
<SENT sid="5" pm="."><plain>Currently used oral <z:chebi fb="0" ids="35526">antidiabetic</z:chebi> agents such as sulphonylureas, <z:chebi fb="0" ids="3095">biguanides</z:chebi> (<z:chebi fb="0" ids="6801">metformin</z:chebi>) and the <z:chebi fb="0" ids="50864">thiazolidinediones</z:chebi> (<z:chebi fb="0" ids="50122">rosiglitazone</z:chebi>, <z:chebi fb="0" ids="8228">pioglitazone</z:chebi>) commonly target fasting <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> and have limited additive effects on postprandial glycaemia </plain></SENT>
<SENT sid="6" pm="."><plain>In contrast, alpha-glucosidase inhibitors can reduce postprandial <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> but gastrointestinal side effects restrict their use </plain></SENT>
<SENT sid="7" pm="."><plain>The development of new agents to control postprandial <z:chebi fb="105" ids="17234">glucose</z:chebi> excursions could be considered as an additional objective for the management of Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="8" pm="."><plain>To this end new short-acting enhancers of insulin secretion such as repaglinide (<z:chebi fb="0" ids="30746">benzoic acid</z:chebi> derivative) and nateglinide (amino acid derivative) have been developed </plain></SENT>
<SENT sid="9" pm="."><plain>The combination of such agents with other complementary modes of action, e.g. an insulin sensitizer, could target better major underlying defects of Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and thereby provide a better approach for controlling the entire glycaemic risk </plain></SENT>
</text></document>